{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:24:15Z","timestamp":1790691855519,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T00:00:00Z","timestamp":1722124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jtct.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T01:18:00Z","timestamp":1718241480000},"page":"876-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-0512","authenticated-orcid":false,"given":"William","family":"Wesson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Saiful Islam","family":"Saif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1747-1404","authenticated-orcid":false,"given":"Carine","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-6573","authenticated-orcid":false,"given":"Mary","family":"McGann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateeha","family":"Furqan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al\u2013Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-1202","authenticated-orcid":false,"given":"Fauzia","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-1873","authenticated-orcid":false,"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10297","key":"10.1016\/j.jtct.2024.06.012_bib0001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jtct.2024.06.012_bib0002","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013b-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2024.06.012_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2024.06.012_bib0004","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.012_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jtct.2024.06.012_bib0006","unstructured":"\u201cHIghlights of Prescribing Information: Abecma (idecabtagene vicleucel): Package Insert. https:\/\/www.fda.gov\/media\/147055\/download.\u201d (accessed February 4, 2024), 2024."},{"key":"10.1016\/j.jtct.2024.06.012_bib0007","unstructured":"U. F. D. Administration. \u201cRIsk Evaluation and Mitigation Strategies. REMS. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems.\u201d (accessed February 4, 2024) 2024."},{"key":"10.1016\/j.jtct.2024.06.012_bib0008","doi-asserted-by":"crossref","unstructured":"\u201cHIghlights of prescribing information. Carvykti (ciltacabtagene autoleucel). Package insert. https:\/\/www.fda.gov\/media\/156560\/download.\u201d (accessed February 4, 2024, 2024).","DOI":"10.51731\/cjht.2024.1029"},{"key":"10.1016\/j.jtct.2024.06.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103453","article-title":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Critical Rev Oncology\/Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.06.012_bib0010","first-page":"160","article-title":"Clinical features of hemophagocytic syndrome following BCMA-CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"51","author":"Zu","year":"2022","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"issue":"7","key":"10.1016\/j.jtct.2024.06.012_bib0011","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.012_bib0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jtct.2024.06.012_bib0013","unstructured":"\u201cNational Cancer Institute. Common terminology criteria for adverse events v5.0 (CTCAE). Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf.\u201d (accessed February 13, 2024."},{"key":"10.1016\/j.jtct.2024.06.012_bib0014","unstructured":"\u201cInternational Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. Available athttps:\/\/www.myeloma.org\/resource-library\/international-myeloma-working-group-imwg-uniform-response-criteria-multiple.\u201d (accessed."},{"issue":"2","key":"10.1016\/j.jtct.2024.06.012_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"14","key":"10.1016\/j.jtct.2024.06.012_bib0016","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.012_bib0017","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy","volume":"70","author":"Marella","year":"2022","journal-title":"Journal of Histochemistry & Cytochemistry"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.06.012_bib0018","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1182\/blood-2022-166058","article-title":"Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience","volume":"140","author":"Sidana","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.012_bib0019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer Journal"},{"issue":"9","key":"10.1016\/j.jtct.2024.06.012_bib0020","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.06.012_bib0021","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2022-165646","article-title":"Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed\/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy","volume":"140","author":"Thibaud","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.06.012_bib0022","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"23","key":"10.1016\/j.jtct.2024.06.012_bib0023","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Advances"},{"issue":"21","key":"10.1016\/j.jtct.2024.06.012_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215149","article-title":"Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2024.06.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8042","article-title":"Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): Real-world experience","volume":"40","author":"Hansen","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.012_bib0026","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2023000435","article-title":"Managing side effects: guidance for use of immunotherapies in multiple myeloma","volume":"2023","author":"Liang","year":"2023","journal-title":"Hematology"},{"issue":"23","key":"10.1016\/j.jtct.2024.06.012_bib0027","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kambhampati","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2024.06.012_bib0028","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA-CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Advances"},{"issue":"8","key":"10.1016\/j.jtct.2024.06.012_bib0029","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Advances"},{"key":"10.1016\/j.jtct.2024.06.012_bib0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2023-182695","article-title":"Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study","volume":"142","author":"Gong","year":"2023","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400469X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672400469X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T18:43:16Z","timestamp":1732214596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672400469X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S266663672400469X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.06.012","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}